Related Experiment Video

Updated: Jun 3, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

Neonatal immunization: where do we stand?

Nicholas Wood1, Claire-Anne Siegrist

  • 1National Centre for Immunisation Research and Surveillance, The Children's Hospital at Westmead and University of Sydney, Sydney, Australia.

Current Opinion in Infectious Diseases
|March 19, 2011
PubMed

Insights

Neonatal immunization shows promise for protecting infants from early life diseases. Research is ongoing to optimize vaccines and overcome hurdles like safety and public acceptance for broader protection.

Area of Science:

  • Immunology
  • Vaccinology
  • Pediatrics

Background:

  • Early life disease poses a significant burden.
  • Advances in understanding neonatal immunology are driving interest in infant vaccination.
  • Maternal and neonatal immunization strategies are being re-evaluated.

Purpose of the Study:

  • To review existing information and recent advances in neonatal human immunization.
  • To highlight the potential of neonatal vaccination as a preventive strategy.
  • To discuss challenges and future research directions in the field.

Main Methods:

  • Review of current literature on neonatal immunology and vaccination.
  • Analysis of recent clinical trial data for neonatal vaccines.
  • Synthesis of findings regarding neonatal immune responses to vaccination.

Main Results:

  • The neonatal immune system is specifically adapted, not immature.
  • Neonatal immune responses favor memory B cell induction and specific T-cell polarization.
  • Recent trials of acellular pertussis and pneumococcal conjugate vaccines at birth show good tolerability and immunogenicity.
  • Vaccine interference was identified as a key issue in combined neonatal vaccination.

Conclusions:

  • Neonatal immunization is a potentially safe and effective method for preventing early life infections.
  • Further research into neonatal immune responses, adjuvants, and formulations is needed.
  • Expanding neonatal vaccination could reduce the burden of diseases like pertussis, rotavirus, and influenza.
  • Key challenges include addressing safety concerns, demonstrating efficacy, and gaining public acceptance.
Abstract

More Related Videos

Mapping Infant Immunity with Minimal Input: Integrative Single-Cell and Multiomic Profiling10:29

Mapping Infant Immunity with Minimal Input: Integrative Single-Cell and Multiomic Profiling

Published on: April 3, 2026

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits (Oryctolagus cuniculus)13:00

Intranasal Immunization and Milk Collection in Studies of Maternal Immunization in New Zealand White Rabbits (Oryctolagus cuniculus)

Published on: July 31, 2021

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Vaccinations01:51

Vaccinations

Overview
Vaccines01:21

Vaccines

Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...